FDA Approves Daratumumab and Hyaluronidase-fihj for High-risk Smoldering Multiple Myeloma

On November 6, the FDA approved daratumumab and hyaluronidase-fihj for adults with high-risk smoldering multiple myeloma.

For more information, read the FDA announcement and the Janssen Biotech press release.

Posted on 11/7/2025